Key Questions on Cancer and Genetics
Concluding our 4-part 2022 interview series on cancer, Dr. Achim Regenauer answers questions for Life underwriters on cancer and genetics, questions relating both to cause and to advances in clinical medicine.
cancer underwriting
Multiparametric MRI and Prostate Cancer
Multiparametric magnetic resonance imaging (mpMRI) is an imaging tool with growing use in diagnosis, risk assessment, and management of individuals with prostate cancer. Explore current challenges with prostate cancer detection and diagnosis, and the role of mpMRI.
Key Questions on Advances in Cancer Therapy
In this third interview of a 4-part series, Dr. Achim Regenauer answers questions relevant to Life & Health underwriters on advances in cancer therapy.
Missed Cancer Screenings from COVID Flash a Warning to US Life Expectancy
The global pandemic’s toll on cancer diagnoses and what it may mean for the future of US life expectancy
Key Questions on Advances in Cancer Diagnostics
In this second interview of a 4-part series, Dr. Achim Regenauer answers questions relevant to Life & Health underwriters on advances in cancer diagnostics.
Key Questions on General Cancer Trends
In this first interview of a 4-part series, Dr. Achim Regenauer answers questions relevant to Life & Health underwriters on general cancer trends, including trends relating to incidence, detection at earlier stages and overdiagnosis.
Global Cancer Trends – A Fast-changing Risk Landscape
In this, the first of a 4-part series of insurance-focused articles on cancer, Dr. Achim Regenauer, Chief Medical Officer, focuses on how these advances translate into high-level trends, and why they are so important to Life & Health insurance – all in a concise bulleted format, so there’s no need to wade through complex medical descriptions or interpret sensationalized headlines.
Study Moves us a Step Closer to the Early Detection of Multiple Cancers via a Simple Blood Test
Dr. Achim Regenauer shares an overview of this important study’s findings and his perspective on the impact on cancer detection and Life & Health insurance.
The Promise of Liquid Biopsy in Advancing Cancer Diagnosis and Treatment
RGA’s consultant oncologist, Dr. Radi Counsell, discusses the ways liquid biopsies will change the face of cancer care, from screening and diagnosis to treatment monitoring and surveillance of survivors. Dr. Counsell also examines underwriting and claims adjudication implications of this emerging technology.
Diagnosis – Colon Cancer: Five Personal Lessons from an Underwriter and Survivor
Cancer is an abstract idea in underwriting, until it happens to the underwriter. Get a candid and highly personal perspective, which was first offered at the AHOU 2021 Annual Conference.